CAR T cells are being included in clinical trials targeting IL-13R alpha, which is expressed on gliomas and medulloblastomas not on normal CNS tissue, GD2 for osteosarcoma, and HER2, which is highly expressed in osteosarcoma and some cases of medulloblastoma. The gene discussed is ERBB2; the disease is medulloblastoma.